Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Revenue: NT$6.21 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
50 GF Score
Price NT$74.10
GF Value NT$107.99
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Revenue?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 +2.07% 50 Revenue is NT$6.21 Mil as of Jun. 2026. GuruFocus rates ROCO:7427 with a GF Score™ of 50/100 and a GF Value™ of NT$107.99 (Possible Value Trap). The stock has 4 warning signs investors should review.

Great Novel Therapeutics Biotech & Medicals's revenue for the six months ended in Jun. 2026 was NT$5.63 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$6.21 Mil. Great Novel Therapeutics Biotech & Medicals's Revenue per Share for the six months ended in Jun. 2026 was NT$0.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.12.

During the past 12 months, the average Revenue per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 205.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 8 years, Great Novel Therapeutics Biotech & Medicals's highest 3-Year average Revenue per Share Growth Rate was 56.00% per year. The lowest was -51.40% per year. And the median was 15.00% per year.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Great Novel Therapeutics Biotech & Medicals Revenue Related Terms


Great Novel Therapeutics Biotech & Medicals Revenue Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Revenue Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.63 0.54 4.85 1.69 1.21

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 1.16 0.62 0.58 5.63

ROCO:7427 vs VRTX, REGN, MRNA: Revenue Comparison

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Revenue distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Revenue falls into.


ROCO:7427
50GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$6.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of NT$6.21 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Revenue of NT$6.21 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Revenue too high?
Great Novel Therapeutics Biotech & Medicals' current Revenue is NT$6.21 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Revenue compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Revenue of NT$6.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Revenue is NT$6.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Possible Value Trap. The stock's GF Value™ is NT$107.99, compared to a current price of NT$74.10 — trading 31.4% below its estimated fair value. The current Revenue is NT$6.21 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Revenue is NT$6.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be undervalued. The current stock price of NT$74.10 is trading 31.4% below its estimated GF Value™ of NT$107.99. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Possible Value Trap.

Key valuation signals for ROCO:7427:

  • Revenue: NT$6.21 Mil
  • GF Value™: NT$107.99 vs. price of NT$74.10 (31.4% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
50GF Score

Get the complete analysis for ROCO:7427

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.10
Price
NT$107.99
GF Value